Anti-obesity medications and investigational agents: an obesity medicine association (OMA) clinical practice statement (CPS) 2022
In the early postoperative phase in rodents, increases are observed in the hepatic expression of lipid oxidative genes as well as in the downregulation of lipogenic genes (such as Cd36 and Scd1 ) after RYGB and VSG 35
IEEE Trans
They are a good choice for those who want sustained weight loss
They are generally safe for most people, but not recommended for individuals with a history of medullary thyroid cancer, MEN2, pancreatitis, severe kidney or liver disease, or those who are pregnant or breastfeeding. What are the most common side effects of GLP-1 drugs
The model of BMI-loss efficacy demonstrated good performance in the self-report data, explaining 25% of the variance ( R 2 ) in both the training set and held out test set, with most of the variance explained by non-genetic factors (Supplementary Table 20)
